CVS Health Gains Momentum as Medicare Payment Rates Beat Expectations

CVS Health (NYSE: CVS) is seeing a resurgence in investor confidence following a final ruling from the Centers for Medicare & Medicaid Services (CMS) regarding provider payment rates. The agency finalized a 2.5% escalation in payments, a stark contrast to the initial proposal of 0.09% that had previously triggered a sharp sell-off in healthcare stocks. The adjustment is particularly critical for CVS due to its ownership of Aetna, a major provider of Medicare Advantage plans. The discrepancy between the proposed and final rates represents an additional $13 billion in payments for insurers across the industry, mitigating concerns that rising operational costs would severely squeeze profit margins. Management has maintained its 2026 adjusted earnings per share (EPS) guidance between $7.00 and $7.20. While some analysts suggest EPS could reach as high as $7.40, the current valuation remains low relative to peers. CVS is currently trading at approximately 11 times forward earnings, while competitors like UnitedHealth Group and Humana trade in the 15 to 20 times range. Market analysts suggest that if CVS can bridge this valuation gap—moving toward a multiple of 13 or 14 times forward earnings—the stock price could reasonably climb toward the $90 to $100 range. Additionally, the company continues to offer a 3.4% forward dividend yield, providing a steady return for investors during this recovery phase.